source · text/markdown
source_b31783d0ee464061
sha256 92377625cd4e3fa1f0f0eda768603f21d0f0ef1a6b929d651d11b6950a99ba9d
by researka:v2 · 2026-06-06 04:10:35.156002+04:00
# Research Synthesis: Extracellular Matrix Stiffening — full paper ## Abstract This paper synthesizes extracellular matrix stiffening as an aging-related intervention across 59 accepted source papers and 1325 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 50 adjacent clinical sources, and 7 mechanistic or model-system sources, with 1051 cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, immune and inflammation, immune outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that extracellular matrix stiffening remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-extracellular_matrix_stiffening-v06-DAILY-2026-06-06T00-02-32Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-06. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `extracellular matrix stiffening AND aging AND human` - `extracellular matrix stiffening AND older adults` - `extracellular matrix stiffening AND randomized controlled trial` - `extracellular matrix AND aging AND human` - `extracellular matrix AND older adults` - `extracellular matrix AND randomized controlled trial` - `tissue stiffness AND aging AND human` - `tissue stiffness AND older adults` - `tissue stiffness AND randomized controlled trial` - `vascular stiffness AND aging AND human` ### Eligibility criteria - Sources whose primary content addresses extracellular matrix stiffening. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 586 records in the receipt-candidate union, 191 were classified as source candidates and 59 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 586 | | Classified source candidates | 191 | | No extractable claims | 135 | | None-only claim binding | 33 | | Mixed partial-or-none claim-binding candidates | 177 | | Partial-only claim-binding candidates | 30 | | Strict high-confidence sources | 20 | | Admitted final sources | 59 | ### Exclusion reasons - Non-traceable findings (claim could not be linked to source text): 0 records. - Wrong population / off-topic sources excluded at screening. - Duplicate records deduplicated by DOI / PMID before screening. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, immune, immune and inflammation, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Contextual Adjacent Evidence | n=46; claims=816 | no extracted directional signal in 46/46 sources | 40 indirect; 4 mechanistic; 2 review | limited corpus depth in this outcome class | | Immune and Inflammation | n=5; claims=160 | no extracted directional signal in 5/5 sources | 5 indirect | limited corpus depth in this outcome class | | Immune | n=3; claims=209 | no extracted directional signal in 3/3 sources | 2 indirect; 1 mechanistic | limited corpus depth in this outcome class | | Skeletal, Fracture, and Bone | n=3; claims=122 | no extracted directional signal in 3/3 sources | 2 indirect; 1 mechanistic | limited corpus depth in this outcome class | | Longevity | n=1; claims=11 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Safety and Comorbidity | n=1; claims=7 | no extracted directional signal in 1/1 sources | 1 mechanistic | single-source slice; hypothesis-generating | This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate. ### Contextual Adjacent Evidence Outcomes 46 included sources were assigned to this outcome class. Directional coding: null=46. Directness coding: indirect=40, mechanistic=4, review=2. ### Immune Inflammation Outcomes 5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=5. ### Immune Outcomes 3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, mechanistic=1. ### Skeletal Fracture Bone Outcomes 3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, mechanistic=1. ### Longevity Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1. ### Safety Comorbidity Outcomes 1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: mechanistic=1. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus contains no randomized controlled trials and no prospective interventional studies with hard clinical endpoints such as mortality, cardiovascular events, or functional disability. All 59 included studies are either preclinical mechanistic investigations (e.g., Lee 2025, Moudt 2022) or observational cohorts (e.g., Alfano 2023, Ahmadi 2026), meaning the synthesis cannot establish causal directionality for extracellular matrix stiffening in human disease. The absence of randomized evidence precludes any estimate of treatment effect magnitude, and conclusions that depend on associational data must be interpreted with caution given the well-recognized limitations of surrogate endpoints (Ioannidis 2005). Single-trial generalization risk is substantial across multiple outcome domains within this corpus. For example, skeletal fracture and bone outcomes are supported by only two observational cohorts — Schurman 2026 and Ahmadi 2026 — alongside one preclinical study (Pereira 2022), while immune mechanistic evidence rests almost entirely on a single in-vitro investigation (Lee 2025). When only one or two studies inform a domain, replication within the corpus is impossible, and apparent consistency may reflect shared methodological biases rather than biological robustness. Population specificity further constrains external validity. Nearly all clinical studies enrolled adults with pre-existing conditions — atrial fibrillation (Alfano 2023), coronary artery disease (Kologrivova 2023), aortic regurgitation (Sadaba 2025), or cancer (Llerena 2025, Saleh 2026) — while preclinical studies used mouse models (Moudt 2022, Zhu 2024) or in-vitro cell systems (Thomas 2025, Conway 2023). No study enrolled healthy older adults to examine whether ECM stiffening independently predicts frailty, sarcopenia, or mobility decline in community-dwelling populations. Consequently, the synthesis cannot address whether extracellular matrix stiffening contributes to age-related functional decline outside of established disease contexts. Several clinically relevant endpoints were not measured in any study within the corpus. No study reported gait speed, handgrip strength, or other standard mobility and sarcopenia metrics (Cruz-Jentoft 2019), and no study assessed fall risk or patient-reported quality of life. The mechanistic evidence linking ECM stiffness to immune cell behavior (Lee 2025) and inflammation (Alfano 2023, Hu 2022) has not been translated into clinical outcomes such as infection incidence or inflammatory biomarker trajectories in intervention trials. Similarly, although ECM stiffening has been mechanistically linked to cancer progression (Xie 2025, Wang 2025c) and organ fibrosis (Junior 2023, Sun 2024), this corpus contains no longitudinal studies tracking whether biomechanical ECM changes precede clinical disease onset — leaving the directionality of these associations unresolved. ## Conclusion For extracellular matrix stiffening, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 59 included sources on Extracellular matrix stiffening across 6 outcome classes and 1051 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 59 curated reference papers, the evidence base for Extracellular matrix stiffening shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Extracellular matrix stiffening anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest unresolved contrast is the agreement between Zhu 2023 and Zhang 2023b on contextual adjacent evidence (severity 1/5), which defines the boundary condition future studies must test rather than smooth over. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | null | direct interventional hard-endpoint gap | | immune | 0 | 3 | null | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 46 | null | direct interventional hard-endpoint gap | | immune and inflammation | 0 | 5 | null | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 1 | null | direct interventional hard-endpoint gap | | skeletal, fracture, and bone | 0 | 3 | null | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P2 | immune: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null | | P3 | contextual adjacent evidence: direct interventional hard-endpoint gap | 0 direct and 46 indirect sources; direction profile: null | | P4 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 5 indirect sources; direction profile: null | | P5 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | ### Next-Study Design Recommendation The next high-yield study for Extracellular matrix stiffening should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Ahmadi 2026; tier=B2; directness=indirect; endpoint=skeletal fracture bone; direction=null; representative statistic=P = 0.001. - Alfano 2023; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=P < 0.001. - Zhu 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001. - Loescher 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null. - Sadaba 2025; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=P = 0.0003. - Sun 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01. - Zhu 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001. - Li 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001. - Xie 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001. - Wu 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Repeated application of passive mechanical stress produces selective metabolic and extracellular matrix adaptations in human skeletal muscle but does not prevent disuse-induced atrophy: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=82. - The Role of Extracellular Matrix and Inflammation in the Stratification of Bleeding and Thrombotic Risk of Atrial Fibrillation on Oral Anticoagulant Therapy: Insights from Strat-Af Study: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=70. - Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=48. - Titin governs myocardial passive stiffness with major support from microtubules and actin and the extracellular matrix: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=44. - The Presence of Adipose Tissue in Aortic Valves Influences Inflammation and Extracellular Matrix Composition in Chronic Aortic Regurgitation: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=41. - Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=39. - Effect of Extracellular Matrix Stiffness on Candesartan Efficacy in Anti-Fibrosis and Antioxidation: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=39. - Adjusting the stiffness of a cell-free hydrogel system based on tissue-specific extracellular matrix to optimize adipose tissue regeneration: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=38. - Extracellular matrix stiffness reduces DNA 6 ma level to facilitate colorectal cancer progression via disrupting P53 binding to CDKN1A promoter: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=37. - Extracellular Matrix Stiffness-Induced Mechanotransduction of Capillarized Liver Sinusoidal Endothelial Cells: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=36. - Extracellular Matrix Stiffness and TGFβ2 Regulate YAP/TAZ Activity in Human Trabecular Meshwork Cells: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=32. - Altered extracellular matrix structure and elevated stiffness in a brain organoid model for disease: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=28. - Efficacy of decellularized extracellular matrix (dECM) for articular cartilage repair in osteoarthritis (OA): a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=26. - Extracellular matrix stiffness aggravates urethral stricture through Igfbp3/Smad pathway: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=24. - Effects of aging on the biomechanical properties of the lung extracellular matrix: dependence on tissular stretch: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=23. - Tissue and extracellular matrix remodeling of the subchondral bone during osteoarthritis of knee joints as revealed by spatial mass spectrometry imaging: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=22. - Defined extracellular matrix compositions support stiffness-insensitive cell spreading and adhesion signaling: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=20. - Extracellular Matrix Tissue Patch for Pulmonary Artery Repair in Pediatric Cardiac Surgery: A Single-Center Experience: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=19. - 3D Printing of Extracellular Matrix‐Based Multicomponent, All‐Natural, Highly Elastic, and Functional Materials toward Vascular Tissue Engineering: outcome=immune; directness=indirect; tier=B2; direction=null; claims=19. - Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=19. - Effect of miRNA-218-5p on Proliferation, Migration, Apoptosis and Inflammation of Vascular Smooth Muscle Cells in Abdominal Aortic Aneurysm and Extracellular Matrix Protein: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=17. - In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=16. - Lysyl-Oxidase Dependent Extracellular Matrix Stiffness in Hodgkin Lymphomas: Mechanical and Topographical Evidence: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=15. - Tissue response and clinical outcomes after cardiovascular use of porcine small intestinal small intestinal submucosal extracellular matrix: a systematic review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=13. - Association of Epicardial Adipose Tissue Adipocytes Hypertrophy with Biomarkers of Low-Grade Inflammation and Extracellular Matrix Remodeling in Patients with Coronary Artery Disease: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=13. - Key role for Rac in the early transcriptional response to extracellular matrix stiffness and stiffness-dependent repression of ATF3: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12. - Survivin regulates intracellular stiffness and extracellular matrix production in vascular smooth muscle cells: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12. - Extracellular Matrix Tissue Patch for Aortic Arch Repair in Pediatric Cardiac Surgery: A Single-Center Experience: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=11. - Suppression of METTL3 expression attenuated matrix stiffness-induced vaginal fibroblast-to-myofibroblast differentiation and abnormal modulation of the extracellular matrix in pelvic organ prolapse: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=11. - Sox9 Accelerates Vascular Aging by Regulating Extracellular Matrix Composition and Stiffness: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=10. - Ecliptasaponin A attenuates renal fibrosis by regulating the extracellular matrix of renal tubular cells: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=10. - Extracellular matrix stiffness regulates colorectal cancer progression via HSF4: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=10. - CD248 ‐expressing cancer‐associated fibroblasts induce non‐small cell lung cancer metastasis via Hippo pathway‐mediated extracellular matrix stiffness: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=10. - An Extracellular Matrix Aging Clock Based on Circulating Matrisome Proteins Predicts Biological Aging and Disease: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=9. - Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=9. - Extracellular matrix stiffness mediates uterine repair via the Rap1a/ARHGAP35/RhoA/F-actin/YAP axis: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8. - Polycystin‐1 Mutant Alters Mechanotransduction in Response to Collagen and Extracellular Matrix Stiffness via Daam1‐Dependent Microfilament Remodeling: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8. - Multi-Step Extracellular Matrix Remodelling and Stiffening in the Development of Idiopathic Pulmonary Fibrosis: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=7. - Vascular smooth muscle cell senescence accelerates medin aggregation via small extracellular vesicle secretion and extracellular matrix reorganization: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6. - Two-dimensional vascularized liver organoid on extracellular matrix with defined stiffness for modeling fibrotic and normal tissues: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=5. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 1 agreement: Zhu 2023 vs Zhang 2023b; Zhu 2023 (null) vs Zhang 2023b (null) on contextual other - Severity 1 agreement: Zhu 2023 vs Li 2023b; Zhu 2023 (null) vs Li 2023b (null) on contextual other - Severity 1 agreement: Zhu 2023 vs Krajnik 2023; Zhu 2023 (null) vs Krajnik 2023 (null) on contextual other - Severity 1 agreement: Zhu 2023 vs Conway 2023; Zhu 2023 (null) vs Conway 2023 (null) on contextual other - Severity 1 agreement: Zhu 2023 vs Dang 2023; Zhu 2023 (null) vs Dang 2023 (null) on contextual other - Severity 1 agreement: Zhu 2023 vs Ozcebe 2023; Zhu 2023 (null) vs Ozcebe 2023 (null) on contextual other - Severity 1 agreement: Zhu 2023 vs Linssen 2023; Zhu 2023 (null) vs Linssen 2023 (null) on contextual other - Severity 1 agreement: Zhu 2023 vs Li 2023c; Zhu 2023 (null) vs Li 2023c (null) on contextual other Additional corpus sources included animal/preclinical evidence; additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Li 2022, Zur 2025, Wang 2025, Ulldemolins 2024, Isik 2023, Gadki 2026, Alfano 2022, Bruun 2025, Wang 2025b, Gadki 2025, Faleeva 2024, Wu 2024b, Sun 2025, Coenen 2026, Markey 2023, Zhou 2025, Zhang 2023, Harmon 2024, Whitehead 2022, Ma 2024, Wolfram 2025, Pulze 2022, Machalinski 2024, Konno 2022, Zu 2024, Jahin 2023, Zhang 2024, Irfan 2025, Smith 2025, Sabnis 2026. ## References - **Lee 2025.** _Harringtonine Attenuates Extracellular Matrix Degradation, Skin Barrier Dysfunction, and Inflammation in an In Vitro Skin Aging Model._ Current Issues in Molecular Biology, 2025. DOI: 10.3390/cimb47080642. PMID: 40864795. - **Ahmadi 2026.** _Repeated application of passive mechanical stress produces selective metabolic and extracellular matrix adaptations in human skeletal muscle but does not prevent disuse-induced atrophy._ Function, 2026. DOI: 10.1152/function.109.2025. PMID: 42013026. - **Alfano 2023.** _The Role of Extracellular Matrix and Inflammation in the Stratification of Bleeding and Thrombotic Risk of Atrial Fibrillation on Oral Anticoagulant Therapy: Insights from Strat-Af Study._ Journal of Clinical Medicine, 2023. DOI: 10.3390/jcm12216866. PMID: 37959331. - **Thomas 2025.** _In vitro and in vivo biocompatibility of a porcine cholecystic extracellular matrix (CECM) membrane for tissue regeneration._ BDJ Open, 2025. DOI: 10.1038/s41405-025-00370-4. PMID: 41068084. - **Moudt 2022.** _Progressive aortic stiffness in aging C57Bl/6 mice displays altered contractile behaviour and extracellular matrix changes._ Communications Biology, 2022. DOI: 10.1038/s42003-022-03563-x. PMID: 35710942. - **Zhu 2024.** _Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy._ Cardiovascular Diabetology, 2024. DOI: 10.1186/s12933-024-02369-x. PMID: 39049086. - **Loescher 2023.** _Titin governs myocardial passive stiffness with major support from microtubules and actin and the extracellular matrix._ Nature Cardiovascular Research, 2023. DOI: 10.1038/s44161-023-00348-1. PMID: 39196092. - **Sadaba 2025.** _The Presence of Adipose Tissue in Aortic Valves Influences Inflammation and Extracellular Matrix Composition in Chronic Aortic Regurgitation._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26073128. PMID: 40243913. - **Zhu 2023.** _Effect of Extracellular Matrix Stiffness on Candesartan Efficacy in Anti-Fibrosis and Antioxidation._ Antioxidants, 2023. DOI: 10.3390/antiox12030679. PMID: 36978927. - **Sun 2024.** _Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction._ Hepatology Communications, 2024. DOI: 10.1097/HC9.0000000000000564. PMID: 39470347. - **Li 2023.** _Adjusting the stiffness of a cell-free hydrogel system based on tissue-specific extracellular matrix to optimize adipose tissue regeneration._ Burns & Trauma, 2023. DOI: 10.1093/burnst/tkad002. PMID: 36873282. - **Xie 2025.** _Extracellular matrix stiffness reduces DNA 6 ma level to facilitate colorectal cancer progression via disrupting P53 binding to CDKN1A promoter._ Experimental Hematology & Oncology, 2025. DOI: 10.1186/s40164-025-00704-w. PMID: 40867005. - **Wu 2024.** _Extracellular Matrix Stiffness-Induced Mechanotransduction of Capillarized Liver Sinusoidal Endothelial Cells._ Pharmaceuticals, 2024. DOI: 10.3390/ph17050644. PMID: 38794214. - **Saleh 2026.** _A Vascular–Extracellular Matrix Molecular Program Identifies High-Risk Diffuse Glioma Across Independent Multi-Omics._ Cancers, 2026. DOI: 10.3390/cancers18101652. PMID: 42193012. - **Li 2022.** _Extracellular Matrix Stiffness and TGFβ2 Regulate YAP/TAZ Activity in Human Trabecular Meshwork Cells._ Frontiers in Cell and Developmental Biology, 2022. DOI: 10.3389/fcell.2022.844342. PMID: 35300422. - **Zur 2025.** _Altered extracellular matrix structure and elevated stiffness in a brain organoid model for disease._ Nature Communications, 2025. DOI: 10.1038/s41467-025-59252-w. PMID: 40312467. - **Wang 2025.** _Efficacy of decellularized extracellular matrix (dECM) for articular cartilage repair in osteoarthritis (OA): a systematic review and meta-analysis._ Journal of Orthopaedic Surgery and Research, 2025. DOI: 10.1186/s13018-025-05881-2. PMID: 40380305. - **Li 2023b.** _Extracellular matrix stiffness aggravates urethral stricture through Igfbp3/Smad pathway._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-41584-6. PMID: 37653219. - **Ulldemolins 2024.** _Effects of aging on the biomechanical properties of the lung extracellular matrix: dependence on tissular stretch._ Frontiers in Cell and Developmental Biology, 2024. DOI: 10.3389/fcell.2024.1381470. PMID: 38645411. - **Schurman 2026.** _Tissue and extracellular matrix remodeling of the subchondral bone during osteoarthritis of knee joints as revealed by spatial mass spectrometry imaging._ Bone Research, 2026. DOI: 10.1038/s41413-025-00495-0. PMID: 41587965. - **Conway 2023.** _Defined extracellular matrix compositions support stiffness-insensitive cell spreading and adhesion signaling._ Proceedings of the National Academy of Sciences of the United States of America, 2023. DOI: 10.1073/pnas.2304288120. PMID: 37844244. - **Isik 2023.** _3D Printing of Extracellular Matrix‐Based Multicomponent, All‐Natural, Highly Elastic, and Functional Materials toward Vascular Tissue Engineering._ Advanced Healthcare Materials, 2023. DOI: 10.1002/adhm.202203044. PMID: 37014809. - **Llerena 2025.** _Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC._ Clinical Cancer Research, 2025. DOI: 10.1158/1078-0432.CCR-25-1098. PMID: 40932382. - **Gadki 2026.** _Extracellular Matrix Tissue Patch for Pulmonary Artery Repair in Pediatric Cardiac Surgery: A Single-Center Experience._ Journal of Clinical Medicine, 2026. DOI: 10.3390/jcm15031177. PMID: 41682863. - **Pereira 2022.** _Preservation of the naïve features of mesenchymal stromal cells in vitro: Comparison of cell-and bone-derived decellularized extracellular matrix._ Journal of Tissue Engineering, 2022. DOI: 10.1177/20417314221074453. PMID: 35154631. - **Hu 2022.** _Effect of miRNA-218-5p on Proliferation, Migration, Apoptosis and Inflammation of Vascular Smooth Muscle Cells in Abdominal Aortic Aneurysm and Extracellular Matrix Protein._ Iranian Journal of Public Health, 2022. DOI: 10.18502/ijph.v51i11.11166. PMID: 36561253. - **Ozcebe 2023.** _In need of age‐appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes._ Aging Cell, 2023. DOI: 10.1111/acel.13966. PMID: 37803909. - **Alfano 2022.** _Lysyl-Oxidase Dependent Extracellular Matrix Stiffness in Hodgkin Lymphomas: Mechanical and Topographical Evidence._ Cancers, 2022. DOI: 10.3390/cancers14010259. PMID: 35008423. - **Bruun 2025.** _Tissue response and clinical outcomes after cardiovascular use of porcine small intestinal small intestinal submucosal extracellular matrix: a systematic review._ Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2025.1532157. PMID: 40636827. - **Kologrivova 2023.** _Association of Epicardial Adipose Tissue Adipocytes Hypertrophy with Biomarkers of Low-Grade Inflammation and Extracellular Matrix Remodeling in Patients with Coronary Artery Disease._ Biomedicines, 2023. DOI: 10.3390/biomedicines11020241. PMID: 36830779. - **Krajnik 2023.** _Survivin regulates intracellular stiffness and extracellular matrix production in vascular smooth muscle cells._ APL Bioengineering, 2023. DOI: 10.1063/5.0157549. PMID: 37868708. - **Dang 2023.** _Key role for Rac in the early transcriptional response to extracellular matrix stiffness and stiffness-dependent repression of ATF3._ Journal of Cell Science, 2023. DOI: 10.1242/jcs.260636. PMID: 37737020. - **Wang 2025b.** _Suppression of METTL3 expression attenuated matrix stiffness-induced vaginal fibroblast-to-myofibroblast differentiation and abnormal modulation of the extracellular matrix in pelvic organ prolapse._ Chinese Medical Journal, 2025. DOI: 10.1097/CM9.0000000000003409. PMID: 39863917. - **Gadki 2025.** _Extracellular Matrix Tissue Patch for Aortic Arch Repair in Pediatric Cardiac Surgery: A Single-Center Experience._ Journal of Clinical Medicine, 2025. DOI: 10.3390/jcm14113955. PMID: 40507716. - **Li 2023c.** _Ecliptasaponin A attenuates renal fibrosis by regulating the extracellular matrix of renal tubular cells._ In Vitro Cellular & Developmental Biology. Animal, 2023. DOI: 10.1007/s11626-023-00803-0. PMID: 37831322. - **Faleeva 2024.** _Sox9 Accelerates Vascular Aging by Regulating Extracellular Matrix Composition and Stiffness._ Circulation Research, 2024. DOI: 10.1161/CIRCRESAHA.123.323365. PMID: 38179698. - **Wu 2024b.** _CD248 ‐expressing cancer‐associated fibroblasts induce non‐small cell lung cancer metastasis via Hippo pathway‐mediated extracellular matrix stiffness._ Journal of Cellular and Molecular Medicine, 2024. DOI: 10.1111/jcmm.70025. PMID: 39164826. - **Wang 2025c.** _Extracellular matrix stiffness regulates colorectal cancer progression via HSF4._ Journal of Experimental & Clinical Cancer Research : CR, 2025. DOI: 10.1186/s13046-025-03297-8. PMID: 39881364. - **Sun 2025.** _Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis._ Cell Death & Disease, 2025. DOI: 10.1038/s41419-025-07697-8. PMID: 40368918. - **Coenen 2026.** _An Extracellular Matrix Aging Clock Based on Circulating Matrisome Proteins Predicts Biological Aging and Disease._ Aging Cell, 2026. DOI: 10.1111/acel.70474. PMID: 41986913. - **Markey 2023.** _Retinal Progenitor Cells Exhibit Cadherin-Dependent Chemotaxis across Transplantable Extracellular Matrix of In Vitro Developmental and Adult Models._ Journal of Tissue Engineering and Regenerative Medicine, 2023. DOI: 10.1155/2023/1381620. PMID: 40226407. - **Zhou 2025.** _Polycystin‐1 Mutant Alters Mechanotransduction in Response to Collagen and Extracellular Matrix Stiffness via Daam1‐Dependent Microfilament Remodeling._ Advanced Science, 2025. DOI: 10.1002/advs.202509846. PMID: 40789101. - **Zhang 2023.** _Extracellular matrix stiffness mediates uterine repair via the Rap1a/ARHGAP35/RhoA/F-actin/YAP axis._ Cell Communication and Signaling : CCS, 2023. DOI: 10.1186/s12964-022-01018-8. PMID: 36691027. - **Harmon 2024.** _Varying Properties of Extracellular Matrix Grafts Impact Their Durability and Cell Attachment and Proliferation in an In Vitro Chronic Wound Model._ Journal of Tissue Engineering and Regenerative Medicine, 2024. DOI: 10.1155/2024/6632276. PMID: 40225755. - **Junior 2023.** _Multi-Step Extracellular Matrix Remodelling and Stiffening in the Development of Idiopathic Pulmonary Fibrosis._ International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms24021708. PMID: 36675222. - **Whitehead 2022.** _Vascular smooth muscle cell senescence accelerates medin aggregation via small extracellular vesicle secretion and extracellular matrix reorganization._ Aging Cell, 2022. DOI: 10.1111/acel.13746. PMID: 36433666. - **Ma 2024.** _Two-dimensional vascularized liver organoid on extracellular matrix with defined stiffness for modeling fibrotic and normal tissues._ Journal of Tissue Engineering, 2024. DOI: 10.1177/20417314241268344. PMID: 39130682. - **Wolfram 2025.** _Extracellular matrix stiffness modulates angiogenic properties of the retinal pigment epithelium._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-27140-4. PMID: 41254090. - **Pulze 2022.** _Spatio-Temporal Changes of Extracellular Matrix (ECM) Stiffness in the Development of the Leech Hirudo verbana._ International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms232415953. PMID: 36555595. - **Machalinski 2024.** _Assessment of Extracellular Matrix Fibrous Elements in Male Dermal Aging: A Ten-Year Follow-Up Preliminary Case Study._ Biology, 2024. DOI: 10.3390/biology13080636. PMID: 39194575. - **Konno 2022.** _The Contributions of Extracellular Matrix and Sarcomere Properties to Passive Muscle Stiffness in Cerebral Palsy._ Frontiers in Physiology, 2022. DOI: 10.3389/fphys.2021.804188. PMID: 35153814. - **Zhang 2023b.** _Adjustable extracellular matrix rigidity tumor model for studying stiffness dependent pancreatic ductal adenocarcinomas progression and tumor immunosuppression._ Bioengineering & Translational Medicine, 2023. DOI: 10.1002/btm2.10518. PMID: 37206224. - **Zu 2024.** _Change in p53 nuclear localization in response to extracellular matrix stiffness._ Smart Medicine, 2024. DOI: 10.1002/SMMD.20240026. PMID: 39776592. - **Linssen 2023.** _Extracellular matrix analysis of fibrosis: A step towards tissue engineering for urethral stricture disease._ PLOS ONE, 2023. DOI: 10.1371/journal.pone.0294955. PMID: 38032942. - **Jahin 2023.** _Extracellular matrix stiffness activates mechanosensitive signals but limits breast cancer cell spheroid proliferation and invasion._ Frontiers in Cell and Developmental Biology, 2023. DOI: 10.3389/fcell.2023.1292775. PMID: 38125873. - **Zhang 2024.** _A Versatile Skin-Derived Extracellular Matrix Hydrogel-Based Platform to Investigate the Function of a Mechanically Isolated Adipose Tissue Stromal Vascular Fraction._ Biomolecules, 2024. DOI: 10.3390/biom14121493. PMID: 39766200. - **Irfan 2025.** _Utilization of a Multi-Tissue Extracellular Matrix in Complex Wound Care in Gaza: A Case Series._ Antibiotics, 2025. DOI: 10.3390/antibiotics14090885. PMID: 41009864. - **Smith 2025.** _COMP Is a Biomarker of Cartilage Destruction, Extracellular Matrix and Vascular Remodeling and Tissue Repair._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26189182. PMID: 41009743. - **Sabnis 2026.** _Tibialis Anterior Muscle Herniation Managed with Ovine Extracellular Matrix Patch: Case Report._ Journal of Orthopaedic Case Reports, 2026. DOI: 10.13107/jocr.2026.v16.i05.7228. PMID: 42131036. ### Background References *Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "ca33ca55-467b-41c9-b22d-473853ddf6df",
"title": "Research Synthesis: Extracellular Matrix Stiffening \u2014 full paper"
}